|Videos|September 2, 2022
Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy
Author(s)Sunandana Chandra, MD, MS
An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.
Advertisement
Episodes in this series
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
FDA approves an updated Ibtrozi label for locally advanced or metastatic ROS1-positive NSCLC, reflecting nearly four years of response data.
Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.
Advertisement
Advertisement